The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS · Delayed Price · Currency is USD
0.0002
-0.0001 (-25.00%)
Aug 1, 2025, 3:06 PM EDT
The Greater Cannabis Company Employees
The Greater Cannabis Company had 1 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$237,941
Market Cap
202.48K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1 | 0 | - |
| Dec 31, 2023 | 1 | 0 | - |
| Dec 31, 2022 | 1 | 0 | - |
| Dec 31, 2021 | 1 | -1 | -50.00% |
| Dec 31, 2020 | 2 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
The Greater Cannabis Company News
- 4 weeks ago - GCANRx Announces Uplisting to New Market Tier - GlobeNewsWire
- 7 months ago - GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing - GlobeNewsWire
- 1 year ago - GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire
- 2 years ago - GCANRx Featured in American Journal of Endocannabinoid Medicine - GlobeNewsWire
- 2 years ago - GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 3 years ago - GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 3 years ago - GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special - GlobeNewsWire
- 3 years ago - GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor - GlobeNewsWire